GreenLight Biosciences Holdings [NASDAQ: GRNA] closed the trading session at $4.16 on 08/04/22. The day’s price range saw the stock hit a low of $4.0106, while the highest price level was $5.8999. The company report on August 1, 2022 that GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
GreenLight Woburn lab 2.
GreenLight’s messenger RNA production process is transferable to large-scale equipment and CMO facilities.
The stocks have a year to date performance of -58.06 percent and weekly performance of 94.39 percent. The stock has been moved at -52.83 percent over the last six months. The stock has performed 108.00 percent around the most recent 30 days and changed -53.05 percent over the most recent 3-months.
If compared to the average trading volume of 293.18K shares, GRNA reached to a volume of 9355074 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about GreenLight Biosciences Holdings [GRNA]:
The Average True Range (ATR) for GreenLight Biosciences Holdings is set at 0.50, with the Price to Sales ratio for GRNA stock in the period of the last 12 months amounting to 1684.25. The Price to Book ratio for the last quarter was 7.43, with the Price to Cash per share for the same quarter was set at 0.68.
GRNA stock trade performance evaluation
GreenLight Biosciences Holdings [GRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 94.39. With this latest performance, GRNA shares gained by 108.00% in over the last four-week period, additionally sinking by -52.83% over the last 6 months – not to mention a drop of -57.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GRNA stock in for the last two-week period is set at 71.49, with the RSI for the last a single of trading hit 86.03, and the three-weeks RSI is set at 59.74 for GreenLight Biosciences Holdings [GRNA]. The present Moving Average for the last 50 days of trading for this stock 3.69, while it was recorded at 2.89 for the last single week of trading, and 7.79 for the last 200 days.
GreenLight Biosciences Holdings [GRNA]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -16.79, with Return on Assets sitting at -14.49.
GreenLight Biosciences Holdings’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.
GreenLight Biosciences Holdings [GRNA]: Insider Ownership positions
There are presently around $127 million, or 24.90% of GRNA stock, in the hands of institutional investors. The top three institutional holders of GRNA stocks are: CORMORANT ASSET MANAGEMENT, LP with ownership of 6,710,540, which is approximately New of the company’s market cap and around 1.10% of the total institutional ownership; VK SERVICES, LLC, holding 5,221,454 shares of the stock with an approximate value of $21.72 million in GRNA stocks shares; and CONTINENTAL GRAIN CO, currently with $20.63 million in GRNA stock with ownership of nearly New of the company’s market capitalization.
35 institutional holders increased their position in GreenLight Biosciences Holdings [NASDAQ:GRNA] by around 28,838,380 shares. Additionally, 60 investors decreased positions by around 15,887,904 shares, while 2 investors held positions by with 14,110,273 shares. The mentioned changes placed institutional holdings at 30,616,011 shares, according to the latest SEC report filing. GRNA stock had 30 new institutional investments in for a total of 26,154,044 shares, while 53 institutional investors sold positions of 13,733,401 shares during the same period.